



Tumour Review

New therapeutic targets in pancreatic cancer

Eleonora Lai^{a,1}, Marco Puzzone^{a,1}, Pina Ziranu^{a,1}, Andrea Pretta^{b,1}, Valentino Impera^{b,1}, Stefano Mariani^{a,1}, Nicole Liscia^{b,1}, Paolo Soro^{a,1}, Francesca Musio^{a,1}, Mara Persano^{a,1}, Clelia Donisi^{a,1}, Simona Tolu^{b,1}, Francesca Balconi^{a,1}, Annagrazia Pireddu^{b,1}, Laura Demurtas^{a,1}, Valeria Pusceddu^{a,1}, Silvia Camera^{b,1}, Francesco Sclafani^{c,2}, Mario Scartozzi^{a,1,*}

^a Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy

^b Medical Oncology Unit, Sapienza University of Rome – University Hospital and University of Cagliari, Cagliari, Italy

^c Gastrointestinal Unit, Jules Bordet Institute, Brussels, Belgium



ARTICLE INFO

Keywords:

Pancreatic cancer
Targeted therapy
Molecular subtypes

ABSTRACT

Pancreatic ductal adenocarcinoma (PDAC) is associated with poor survival. Of all newly diagnosed patients, only about 20% can benefit from a potentially curative surgical resection, the remaining 80% presenting with unresectable locally advanced (LAPC) or metastatic (MPC) disease. Currently, there are limited therapeutic options for LAPC and MPC patients. Furthermore, despite intensive research efforts to better understand the molecular bases of PDAC and the biological relevance of its tumor microenvironment, treatments still largely consist of classical cytotoxic chemotherapy agents.

Several studies of genetic and epigenetic sequencing have demonstrated the existence of 4 molecular PDAC subtypes, with heterogeneous genetic characteristics and different biological behaviour: squamous, pancreatic progenitor, immunogenic and aberrantly differentiated endocrine exocrine (ADEX). These distinct subtypes derive from alterations at multiple levels. Apart from the DNA repair pathway, however, none of these has so far been validated as a clinically relevant therapeutic target.

Also, PDAC is unique from an immunological perspective and many studies have recently tried to elucidate the role of intratumoral effector T-cells, RAS oncogene, immunosuppressive leukocytes and desmoplastic reaction in maintaining the immunological homeostasis of this disease. However, there still remains much to be learned about the mechanisms whereby the pancreatic immune microenvironment promotes immune escape of cancer cells. Furthermore, while therapies targeting the stroma as well as immunotherapies hold promise for the future, these are not yet standard of care.

This review aims to outline the state-of-the-art of LAPC and MPC treatment, highlighting data on the target therapies failure and current ongoing clinical trials on new promising therapeutic strategies.

Introduction

Pancreatic adenocarcinoma (PDAC) is the most common type of pancreatic cancer (PC) [1–3]. PDAC incidence is rising; it is expected to become the second cause of cancer-related death by 2030 and has a

very poor prognosis [4]. More than 80% of patients have an advanced disease at diagnosis, and the 5-year overall survival rate is approximately 7% [5]. Poor survival is attributed to high aggressiveness, intrinsic chemotherapeutic resistance and lack of effectively targetable oncogenic drivers. Systemic chemotherapy is the mainstay of locally

* Corresponding author at: Oncologia Medica, Azienda Ospedaliera Universitaria Cagliari, Presidio Policlinico Universitario “Duilio Casula”, S.S. 554, Km 4,500 Bivio per Sestu, 09042 Monserrato, CA, Italy.

E-mail addresses: ele.lai87@gmail.com (E. Lai), marcopuzzone@gmail.com (M. Puzzone), pziranu@libero.it (P. Ziranu), an.pretta@gmail.com (A. Pretta), vola_90@live.it (V. Impera), mariani.step@gmail.com (S. Mariani), nikina310788@gmail.com (N. Liscia), paol.soro.9@outlook.it (P. Soro), francesca.musio@gmail.com (F. Musio), marapersano@alice.it (M. Persano), cleliadonisi@gmail.com (C. Donisi), simo.tolu@tiscali.it (S. Tolu), frabalconi@gmail.com (F. Balconi), pireddu.annagrazia@tiscali.it (A. Pireddu), lau.demi81@gmail.com (L. Demurtas), valeria.pusce@gmail.com (V. Pusceddu), silvia.camera@hotmail.it (S. Camera), francesco.sclafani@bordet.be (F. Sclafani), marioscartozzi@gmail.com (M. Scartozzi).

¹ Postal address: Oncologia Medica, Azienda Ospedaliera Universitaria di Cagliari, Presidio Policlinico Universitario “Duilio Casula” S.S. 554, Km 4,500 Bivio per Sestu, 09042 Monserrato, Cagliari, Italy.

² Postal Address: Gastrointestinal Unit, Jules Bordet Institute, Boulevard de Waterloo, 125 – B-1000 Brussels, Belgium.

advanced (LAPC) and metastatic (MPC) patients treatment and single-agent gemcitabine had been the standard for more than two decades until first-line FOLFIRINOX and *nab*-paclitaxel/gemcitabine demonstrated better efficacy [6–9]. Targeted therapies play a limited role in PDAC management [10,11]. Therefore, new therapeutic approaches with meaningful impact on patients survival are urgently needed.

Recently, substantial progress was made in the understanding of PDAC genetic background and molecular biology. Up to 4 molecular subgroups have been identified, each with distinct molecular signatures and potential specific therapeutic targets [12]. These valuable research efforts, however, have not yet been matched either by the successful development of novel agents or by the identification of predictive biomarkers that could increase the effectiveness of existing therapies. As a result, PDAC remains refractory to most currently available treatments [13]. Furthermore, the peculiar tumour microenvironment with the excessive desmoplastic stroma represents an important biological barrier for drug delivery and activity [11,13]. In this regard, however, targeting components of the tumour stroma that contribute to desmoplasia emerged as a potentially valid therapeutic approach [14].

This article aims to review the complex and heterogeneous molecular characteristics of PDAC and to discuss novel promising molecular targets and therapeutic agents.

Molecular subtypes of pancreatic cancer

Several studies of genetic/epigenetic sequencing revealed significant molecular heterogeneity among PDAC. Collison et al. considered three molecular subtypes: classical, quasi-mesenchymal, endocrine-like; then, Moffit et al. identified four different molecular entities: classical, basal-like, normal stromal and activated stromal [12,15]. Recently, Bailey et al. suggested the existence of four molecular subtypes with different biological features and prognostic relevance: squamous, pancreatic progenitor, immunogenic and aberrantly differentiated endocrine exocrine (ADEX) (the last two as subclasses of the pancreatic progenitor subtype) [16]. This classification was based on the differential expression of crucial transcription factors and downstream targets in lineage differentiation during pancreatic development. Recently, the Cancer Genome Atlas Research Network performed an integrated genomic, transcriptomic and proteomic characterization of PDAC that identified two main subtypes: basal like/squamous and classical/pancreatic progenitor [17].

The Squamous subtype is characterized by alterations of gene networks involved in inflammation, hypoxia response, metabolic reprogramming, TGF- β signaling, MYC pathway activation, autophagy, TP53 and KDM6A mutations, up-regulated expression of TP63 transcription factor (Δ Np63) and its target genes. Δ Np63 expression is sufficient to induce and sustain the transcriptional signature of the squamous lineage in human PDAC [18]; in addition, RNA-seq identified high expression of TP63 and its target genes as key features in adenocarcinoma pancreatic tumours. Furthermore, hypermethylation and down-regulation of genes involved in the pancreatic endodermal development can also lead to the loss of endodermal identity. Squamous subtype is considered an independent poor prognostic factor.

The Pancreatic progenitor subtype is characterised by high levels of a pivotal transcriptional network for pancreatic endodermal determination and it seems to be triggered by errors in the cells guiding pancreatic development. PDX1 is one of the main transcriptional regulators in the formation of all pancreatic cell types and it appears to play an oncogenic role; moreover, oncogenic KRAS expression in the pancreatic parenchyma leads to neoplasm with increased expression of PDX1 [19].

ADEX is characterized by up-regulation of transcriptional networks involved in later stages of pancreatic development which define the differentiation of exocrine and endocrine lineages. These networks include transcription factors such as NR5A2, MIST1 and RBPJL and genes associated with endocrine differentiation and MODY. NR5A2 might

play a role in the acquisition of the cancer stem cell phenotype and in the PC epithelial-to-mesenchymal transition (EMT), this possibly contributing to the worse clinical outcome [20].

The Immunogenic class is characterised by significant immune infiltrate, largely composed of B and T cells (including both CD8⁺ and regulatory T cells) and up-regulation of PD-1 and CTLA-4 signaling. These data suggest a potential role for immune modulator agents in this specific class. A further sub-classification based on the specific composition of the immune infiltrate might have a prognostic value, but studies are needed to confirm this hypothesis [16].

Both squamous and immunogenic subtype are defined especially by the tumour microenvironment rather than the tumour cells. This aspect confirms the crucial role of microenvironment in PDAC.

Potential targets in pancreatic cancer

PDAC is a genetically and biologically heterogeneous tumour. Recently, emerging evidences demonstrated that a number of cancer genes and signalling pathways are critically involved in the processes of PDAC tumourigenesis and progression and, as such, they may be potentially useful therapeutic targets [21].

Molecular pathways

Transmembrane receptor proteins and downstream signaling cascade

In the last decades, much of the efforts to characterise the key oncogenic signalling pathways of PDAC focused on growth factors and growth factor receptors analysis. The receptor tyrosine kinases (RTKs) activate many pathways, including Ras/MAPK, PI3K/AKT, PLC γ /PKC, and JAK/STATs.

Activating mutations of KRAS are seen in over 90% of PDAC.

The phosphoinositide 3 kinase/AKT/ mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathway is frequently activated in PDAC. This pathway is crucial in many cancer-associated activities and its activation is associated with poor prognosis [22]. Increased AKT activity has been identified in ~60% of PDAC samples, with amplification of the *AKT2* oncogene occurring in 10–20% of cases [23].

Numerous RTKs play an important role in PC, including the epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), insulin-like growth factor receptor (IGFR), tropomyosin receptor kinase (TRK), vascular endothelial growth factor receptor (VEGFR) and PDGFR.

EGFR: EGFR overexpression is detected in up to 90% of PDAC and plays an important role in PDAC recurrence and liver metastasis development. Clinical data suggested that EGFR up-regulation might be associated with a more aggressive tumour behaviour and higher rates of disease recurrence after surgery [24].

FGF/FGFR: The fibroblast growth factor (FGF)/FGFR pathway plays a key role in PDAC development and progression. FGFR1 and FGFR2 are overexpressed in PDAC and they are associated with advanced tumour stage and shorter survival. FGF and FGFR increased levels are associated with up-regulation of *inducible* Nitric Oxide Synthase (iNOS) and tyrosine protein nitration in tumour tissues, confirming the oxidative stress involvement in FGF pathway-mediated PDAC development [21].

IGF/IGFR: In PDAC, high expression of Insulin-like Growth Factor-1 (IGF-1) and IGF1R are associated with high tumour grade and poor survival [24]. The co-expression of IGF1R and EGFR is significantly associated with poor survival in PDAC. Furthermore, IGF-1 is abundant in PDAC patients serum, where it binds to insulin-like growth factor binding proteins (IGFBPs). Recent studies highlighted that high IGF-1/low IGFBP-3 concentrations might be associated with increased PDAC risk, advanced PDAC and poor outcome.

TRK: TRK gene fusions lead to constitutive, ligand-independent downstream pathways activation, tumour cells promotion, proliferation and survival. These alterations, as well as ROS1 fusions, are rare in

pancreatic cancer; however, the real incidence is unknown since routine testing is not standard practice. A study on 47 resected PDAC samples revealed a 66% increased TRK receptor expression compared with normal adjacent tissue. Another work demonstrated a correlation between TrkB expression and increased rates of perineural invasion, positive margin and development of metastasis in resected PDAC [25,26].

VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF)/VEGFR: Angiogenesis is a crucial event in tumour development and progression. VEGF is an angiogenic polypeptide that promotes endothelial cell proliferation and survival by binding to VEGFR-1 and VEGFR-2. Increased expression of VEGF mRNA was reported in PDAC samples this correlating with high micro-vessel density and disease progression [24].

Other pathways

WNT/ β -CATENIN: The Wnt/beta-catenin pathway is involved in many cellular functions such as stem cell regeneration and organogenesis. Wnt pathway aberrant activation has been documented in up to 65% of PDAC. A recent study showed that Wnt signaling enrichment resulted in increased PDAC development and aggressiveness [27,28].

NOTCH: Evidence suggest that Notch plays important oncogenic roles in pancreatic tumourigenesis. Recently, the Notch signaling pathway has been found to directly up-regulate Snail-1 and Slug, thereby inducing epithelial-to-mesenchymal transition (EMT).

ROUNABOUT (ROBO) RECEPTORS/ SLIT GLYCOPROTEIN LIGANDS (SLIT): ROBO/SLIT have been linked to cell adhesion, proliferation and survival. Mutated SLIT-ROBO genes are described in approximately one-third of PDAC patients and are frequently silenced by methylation [29,30].

TRANSFORMING GROWTH FACTOR BETA (TGF- β): TGF- β acts as tumour suppressor gene in non-malignant clones, but it can promote angiogenesis and EMT in cancer cells and it is indeed one of the most important EMT-inducing factors [27]. TGF- β signaling regulates the transcription of target genes through a cascade of events involving SMAD2, 3 and 4 [24].

HEDGEHOG (Hh): The Hh signaling pathway has a critical role in embryonic development and maintenance of adult tissues. Its dysregulation has been highly implicated in tumourigenesis and its overexpression has been found in 70% of PDAC [31], where it promotes tumour growth and metastasis [32]. Interestingly, overexpression of sonic Hh (sHh) ligand is absent in the healthy pancreas but increases dramatically from PanIN stages to invasive adenocarcinoma [31]. Furthermore, several reports demonstrated that Hh pathway activation induces stem cell markers and is involved in EMT enhancement [33].

NEUREGULIN-1 (NRG1): NRG1 is a ligand that interacts with ERBB3 and ERBB4 RTK, stimulating the downstream signaling pathways. In PDAC, NRG1 fusion acts as an oncogenic driver, leading to greater expression of the NRG1 EGF-like domain and promoting the affinity with ERBB2/ERBB3 receptor complexes. Recent data showed the efficacy of ERBB inhibition therapy (e.g afatinib and erlotinib) in NRG1-rearranged PDAC [34].

Tumour-Suppressor genes

Tumour-suppressor genes encode for proteins which generally restrain cell proliferation. Loss of tumour-suppressor function, via mutation or chromosome rearrangement, leads to deregulated cell growth. Tumour suppressor genes which are commonly mutated in sporadic PDAC and can represent useful therapeutic targets include Ink4A, p53 and SMAD4.

TP53: TP53 gene is mutated in 50–75% of PDAC. Mutations of TP53 arise in later-stage PanINs. Lack of p53 activity results in increased rates of genomic aberrations, contributing to PDAC heterogeneity and chemotherapy resistance.

SMAD4 (DPC4): Mutations of SMAD4, a key signal transducer of TGF- β , are seen in approximately 50% of PDAC [24]. SMAD4 loss

occurs late in the process of PanIN progression to carcinoma and influences tumour-stroma interactions [1]. Available data about SMAD4 and its role as a biomarker in PDAC are discordant. Some studies showed improved overall survival (OS) after surgery in patients with SMAD4 expression, while loss of SMAD4 was described as a marker of a more aggressive phenotype with higher potential for metastatic disease progression. Conversely, other studies reported an inverse relation between SMAD4 expression and survival outcomes [27].

DNA repair factors

Particularly interesting in terms of potential therapeutic implications are BRCA and mismatch repair (MMR) gene mutation.

BRCA: Germline mutations of BRCA1 or BRCA2 cause a deficiency in DNA damage repair (DDR). DDR mutations lead to chromosomal instability and tumourigenesis through lack of repair or mis-repair of DNA damage [35]. A number of studies have shown that PDAC is the third most common cancer associated with these mutations after breast and ovarian cancers [36]. The lifetime-risk for PDAC in BRCA2 mutation carriers is estimated to be 3.5–10 times higher than that in the general population. In BRCA1 mutation carriers this risk appears to be lower (about 3.1 times higher than in the general population) [37].

MMR DEFICIENCY: The MMR system plays a pivotal role in the repair of DNA sequence mismatches during replication. Defects in the MMR system (dMMR) causes errors in DNA replication, leading to high burden of mutations especially involving microsatellites (short tandem repeats that are prone to DNA replication errors) and the resulting MSI phenotype. The prevalence of dMMR/MSI in PDAC has been reported to range from 1 to 2% and it has been associated with better survival rates [38].

EMT

EMT is a multistage *trans*-differentiation process which allows highly polarized epithelial cells to undergo multiple biochemical changes to attain a mesenchymal phenotype. During EMT, epithelial cells lose their epithelial markers (E-cadherin, occludin, claudin, and laminin-1) and gain mesenchymal markers (N-cadherin, vimentin, and fibronectin). EMT is classified into three major types; type 3 EMT occurs in carcinoma cells and is considered to be an important event at different stages (dissemination, invasion, intravasation and extravasation) of the metastasis process.

Extracellular Matrix (ECM)

The PC microenvironment plays an important role in terms of tumour growth, invasion, and chemotherapy resistance. It is characterized by dense and firm desmoplasia and extensive immunosuppression [31]. In PDAC, only 10%–20% of the tumour volume is represented by the epithelial/tumour cell component, whereas the remaining volume is constituted by stromal cells, including cancer-associated fibroblasts (CAF), immune cells, endothelial cells, and abundant ECM [27,39].

In particular, CAFs can promote tumour progression and metastatic diffusion by facilitating tumour cell migration and invasion. There are at least two functional CAF entities: the myofibroblasts, characterized by enhanced ECM production and α -smooth muscle actin (α SMA) expression, and the secretory CAFs, involved in the activation of NF- κ B and STAT1 transcription factors. Myofibroblasts contributes to tumour stiffness, hypoxia and avascularization, whereas tumours with prevalence of secretory CAFs are more aggressive, immunosuppressive and chemotherapy-resistant, due to increased proliferation, vascularization, recruitment of MDSCs, stemness induction [40,41].

Furthermore, hyaluronic acid (HA), the major component of normal ECM, is significantly increased in several solid malignancies and has been implicated in tumour progression, treatment resistance, and poor prognosis. HA polymers bind to and trap water molecules, influencing

tissue architecture, malleability, and ECM integrity [42]. Tumour stiffness is enhanced and interstitial fluid pressure increases. These factors enhance resistance to treatment [39].

Cancer Stem Cells

Cancer stem cells (CSCs), a minor subpopulation of tumour cells, are crucial in tumour initiation, progression and therapeutic resistance. Pancreatic CSCs present cell surface markers including CD24, CD44, CD133, ESA, c-Met, CXCR4 and ALDH1 [43] and share a lot of characteristics with normal stem cells like self-renewal capacity and quiescence. Many pathways (Wnt/ β -catenin, sHh and Notch) are known to regulate stem cell self-renewal. CSCs non-dividing G0-state protects them from the cytotoxic potential of chemotherapeutic drugs and represent the biological basis of late tumour relapse following treatment. The mechanisms by which CSCs become drug resistant are largely unknown. It is very likely, however, that drug resistance is mediated by ATP Binding Cassette (ABC) drug transporters, quiescence, detoxifying enzymes, DNA repair ability and anti-apoptotic proteins overexpression [24]. Also, CSCs have an advantage in evading immune detection and elimination. Accumulating evidence indicates that CSCs express low levels of T-cell activation co-stimulatory molecules and high levels of T-cell inhibitory molecules including PD-L1 [43]. Moreover, CSCs exhibit metastasis ability, even if the exact relationship between CSCs and metastasis is not clear yet. This might be secondary to the close association between CSCs and cancer cell EMT as suggested by the presence of common signaling pathways, such as Wnt/ β -catenin and Notch axis.

Clinical trials and future perspectives

Several trials have been conducted and many others are on going to investigate the role of various innovative drugs in PDAC either as monotherapy or in combination with chemotherapy (Fig. 1, Tables 1 and 2)

Transmembrane receptor proteins and downstream signaling cascade inhibitors

Mitogen/extracellular signal-related kinase (MEK) inhibitors (MEKi)

Trametinib is an orally bioavailable, allosteric, reversible and selective inhibitor of MEK1/2. It inhibits MEK-dependent ERK phosphorylation and MEK1/2 activation by preventing Raf phosphorylation of MEK on S217. A randomized, double blind, phase II trial evaluated first-line gemcitabine plus trametinib versus (vs) gemcitabine plus placebo in 160 MPC patients. No significant difference in OS (8,4 vs 6,7 months) and progression free survival (PFS) (16,1 vs 15,1 weeks) was observed between the treatment arms [44].

A phase II study conducted by *Bodoky G et al.* investigated the efficacy and safety of selumetinib, an oral, potent, allosteric, highly selective ATP-uncompetitive MEK1/2 inhibitor, vs capecitabine in LAPC and MPC patients who failed first-line gemcitabine therapy, without demonstrating significant OS and PFS differences [45].

Another phase II trial enrolled 24 MPC first-line therapy progressed patients to receive trametinib and GSK2256098, an oral focal adhesion kinase (FAK) inhibitor. Treatment was well tolerated but no significant efficacy was demonstrated [46].

The potential synergistic role of MEKi and cycline-dependent kinase4/6 inhibitors (CDK4/6i) was investigated [47]. An ongoing phase I/II study will evaluate the role of ribociclib plus trametinib in LAPC or MPC (NCT02703571).

IGFR inhibitors

Ganitumab is an anti-IGF1R monoclonal antibody (mAb) preventing the binding of IGF-1 and IGF-2 to their receptors. In a randomized,

phase 2 trial with gemcitabine plus ganitumab vs gemcitabine plus conatumumab vs gemcitabine plus placebo, 125 MPC patients were enrolled and 40 were treated with first-line ganitumab plus gemcitabine. Treatment was well tolerated and showed numerical improvement in OS (HR:0.67;p = 0.12) and PFS (HR:0.65;p = 0.072) compared to gemcitabine plus placebo [48,49].

The GAMMA Trial, a double-blind, phase 3, randomized study, assessed the efficacy and safety of first-line ganitumab plus gemcitabine. This 3-arm study (gemcitabine + placebo vs gemcitabine + ganitumab 12 mg/kg vs gemcitabine + ganitumab 20 mg/kg) was discontinued prematurely after the results of a pre-planned futility analysis. Median OS (mOS) was 7.2 months in the placebo arm, 7.0 months in the low-dose ganitumab arm and 7.1 months in the high-dose ganitumab arm; similarly, no differences were observed in median PFS (mPFS) (3.7 months, 3.6 months and 3.7 months) [50,51].

The CARRIE trial was a randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy of first-line nab-paclitaxel/gemcitabine in combination with istiratumab (a mAb targeting IGF-1R and ErbB3) compared to nab-paclitaxel/gemcitabine plus placebo in MPC patients with high free serum IGF-1 levels. 88 patients were enrolled; the study failed to show mOS or mPFS improvement in favour of the investigational arm (mOS:8.9 months, mPFS:3.6 months) as compared to the control arm (mOS:11.7 months, mPFS:7.3 months). Similar results were reported for the group of patients with high free IGF-1 serum levels and Heregulin-positive tumours [52].

mTOR inhibitors (mTORi)

A phase II study evaluated the efficacy of single-agent everolimus in patients with gemcitabine-refractory MPC. Although well-tolerated, everolimus showed only minimal clinical activity [53].

A Hellenic Cooperative Oncology Group phase I/II study investigated the combination of gemcitabine with temsirolimus in LAPC and MPC patients; this association resulted feasible with manageable side effects but it didn't show any significant clinical efficacy [54].

TRK inhibitors

Encouraging results were obtained in trials exploring TRK inhibitors. In 2018, a study grouped 55 patients previously enrolled in a protocol with larotrectinib: a phase I study involving adults, a phase I/II study involving children and a phase 2 study in adolescents and adults. These patients had several types of solid tumors with TRK fusion positive molecular profile (only 1 patient had PC). The overall response rate (ORR) was 75% (95%CI:61–85) according to the independent review and 80% (95%CI:67–90) according to investigator assessment. The only PC patient achieved a partial response (PR). Median duration of response and PFS were not reached [25].

Two phase I studies evaluated the safety and efficacy of entrectinib, a TRKA/B/C, ROS proto-oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK) tyrosine kinases inhibitor, in patients with different solid tumours, including PC. Entrectinib was well tolerated; in 3 NTRK1/2/3-rearranged solid tumours, ORR was 100% (CI95%:44–100); in 7 ALK-rearranged solid tumours, ORR was 57% (CI95%:25–84) and in 14 ROS1-rearranged, ORR was 86% (CI95%:60–96). mOS and mPFS were not reached [55].

Other pathways inhibitors

NOTCH inhibitors

Various agents targeting the NOTCH pathway were investigated in PDAC: demcizumab, an anti-DLL4 antibody; tarextumab, a Notch2/3 receptors inhibitor; RO4929097 and MK-0752, two gamma secretase inhibitors.

The YOSEMITE trial was a double blind, three-arm, randomized, phase 2 study where MPC patients were randomly allocated to first-line therapy with gemcitabine and nab-paclitaxel plus either placebo or demcizumab according to two different schedules. Demcizumab was




Fig. 1. Potential targets and drugs for pancreatic cancer treatment.

well tolerated but it didn't provide significant differences in mPFS and mOS [56–58].

The role of tarextumab in combination with first-line gemcitabine plus nab-paclitaxel was evaluated in a randomized, placebo-controlled, phase II study that recruited 177 patients. The addition of tarextumab to nab-paclitaxel and gemcitabine didn't improve OS. In addition, a potential negative effect on PFS and ORR was shown in the subgroup of patients with Notch-3 expression < 25%ile [59].

A Phase II Study of RO4929097, a potent and selective inhibitor of γ -secretase enzyme, preventing the proteolytic cleavage required to activate Notch, was conducted in previously treated MPC. Eighteen patients were recruited but enrollment was stopped after discontinuation of further development of RO4929097 by the Sponsor. Three (25%) of 12 evaluable patients achieved stable disease (SD). The 6-month survival rate was 27.8% (95%CI:9.7–53.5) with a mOS of 4.1 months (95%CI:2.7–5.8 months) and a mPFS of 1.5 months (95%CI:1.3–1.6 months) [60].

A phase I multicenter study enrolled 44 MPC patients who received gemcitabine and MK-0752 as first- or second-line treatment. One patient achieved a confirmed PR and 13 patients had SD [61].

TGF- β inhibitors

A phase Ib/II multinational trial in LAPC and MPC patients who were candidates for first-line gemcitabine chemotherapy investigated the efficacy of galunisertib, the first orally bioavailable small-molecule inhibitor of the type I TGF- β receptor (ALK5) serine/threonine kinase that specifically downregulates the phosphorylation of SMAD2, blocking the activation of the TGF- β pathway. Patients were randomised in a 2:1 ratio to receive gemcitabine plus galunisertib or placebo. The primary endpoint was met, with mOS of 8.9 months in the

galunisertib arm and 7.1 months in the placebo arm (HR = 0.79; 95%CI:0.59–1.09; posterior probability HR < 1 = 0.93) [62].

Further exploration of TGF- β inhibitors in PC is ongoing in a phase I study evaluating galunisertib in combination with the anti-PD-L1 durvalumab (NCT02734160).

Hn inhibitors

A multicenter phase Ib study evaluated in naïve LAPC and MPC the combination of FOLFIRINOX with IPI-926, a potent and specific inhibitor of Smoothened (Smo) transmembrane protein, whose inhibition leads to repression of Hh pathway malignant activation, resulting in decreased desmoplasia and improved chemotherapy delivery to PC. ORR was 67% and patients receiving IPI-926 maintenance showed further declines in CA19-9 levels even after FOLFIRINOX discontinuation. Unfortunately, the study closed prematurely after a separate phase II trial of IPI-926 plus gemcitabine indicated a detrimental effect of this combination [63,64].

Another Hn inhibitor, vismodegib, was studied in combination with gemcitabine in a randomised, placebo-controlled, phase Ib/II trial but combination therapy didn't show any improvement in OS, PFS and ORR over standard treatment [65].

CDK4/6i

Several preclinical studies demonstrated anti-tumor activity of CDK4/6i [66–68]. In particular, in PDAC models palbociclib lead to ECM disruption, tumour cell apoptosis and quiescence, inhibition of metastatic spread and tumour progression [69]. The role of CDK4/6i is currently under evaluation in phase I, II and III studies.

Table 1
Selected pancreatic cancer clinical trials.

Mechanism of action	Drug assessed	Phase of study	Treatment arms	Treatment line	References
MEK1/2 inhibitors	1. trametinib	II	gemcitabine + trametinib vs gemcitabine + placebo	I line	[44]
	2. selumetinib	II	Trametinib + GSK2256098 Capecitabine vs selumetinib	II line LA and MPC after gemcitabine based treatment	[46] [45]
IGFR1- inhibitors	1. ganitumab	III	gemcitabine + placebo vs gemcitabine + ganitumab 12 mg/kg vs gemcitabine + ganitumab 20 mg/kg	I line	[50]
	2. istiratunab	II	gemcitabine + ganitumab vs gemcitabine + conatumumab vs gemcitabine + placebo	I line	[48]
mTOR inhibitors	1. everolimus	II	Gemcitabine + Nab-paclitaxel + istiratunab vs Gemcitabine + Nab-paclitaxel + placebo	First line	[52]
	2. temsirolimus	II	everolimus	Second line	[53]
TRK inhibitors	1. larotrectinib	I/II-II	temsirolimus + gemcitabine	LAPC, first line	[54]
	2. entrectinib	I	larotrectinib	Locally advanced or metastatic tumours after standard treatment	[25]
NOTCH inhibitors	1. dencizumab (anti-DLL4 antibody)	II	entrectinib	All lines for advanced tumours	[55]
	2. tarextumab (Notch2/3 receptors inhibitor)	II	Gemcitabine + Nab-paclitaxel + placebo vs Gemcitabine + Nab-paclitaxel + demcizumab (single 70 day truncated course of demcizumab) vs Gemcitabine + Nab-paclitaxel + demcizumab (two 70 day truncated course of demcizumab)	First line	[58]
TGF-β inhibitors	3. RO4929097 (γ-secretase inhibitor)	II	Gemcitabine + Nab-paclitaxel + tarextumab vs Gemcitabine + Nab-paclitaxel + placebo	First line	[59]
	4. MK-0752 (γ-secretase inhibitor)	I	RO4929097 MK-0752	After first line First and second line	[60] [61]
Hedgehog inhibitors	Galunisertib	Ib-II	Galunisertib + gemcitabine vs gemcitabine + placebo	First line	[62]
	1. IPI-926	II	IPI-926 + gemcitabine	First line	[64]
Poly ADP ribose polymerase inhibitors	2. Vismodegib	Ib-II	IPI-926 + FOLFIRINOX Gemcitabine + vismodegib vs gemcitabine + placebo	LAPC and first line First line	[63] [65]
	1. Olaparib	III	olaparib vs placebo	Maintenance after first line	[71]
Immunotherapy	2. rucaparib	II	Olaparib	Previous gemcitabine treatment	[70]
	3. veliparib	II	Rucaparib	LAPC and MPC after 1–2 chemotherapy regimens	[72]
ECM inhibitors	1. Ipilimumab (anti-CTLA4)	II	Veliparib	Second-third line	[73]
	2. Tremelimumab (anti-CTLA4)	Ib	Veliparib + mFOLFIRI vs Mfolfiri Veliparib + FOLFOX	Second line	[75]
Cancer Stem Cells inhibitors	3. Nivolumab (anti-PD1)	I	Ipilimumab Gemcitabine + ipilimumab	All lines	[74]
	4. Pembrolizumab (anti-PD1)	II	ipilimumab vs ipilimumab + GVAX	All lines First and further lines (previous gemcitabine for first line prohibited)	[78] [82]
ECM inhibitors	5. GVAX (vaccine)	II	Gemcitabine + tremelimumab	gemcitabine for first line (previous gemcitabine-based treatment mandatory)	[81]
	6. Indoximod (anti-IDO)	II	Nivolumab	First line	[79]
Cancer Stem Cells inhibitors	7. PF-04136309 (anti-CCR2)	Ib	Pembrolizumab GVAX → 5FU based CHT + RT	All lines After first line	[80]
	1. Ibrutinib (Bruton's tyrosine kinase inhibitor)	II	Indoximod + gemcitabine + nab-paclitaxel PF-04136309 + FOLFIRINOX	Adjuvant First line	[85] [88]
Cancer Stem Cells inhibitors	2. PEGPH20 (pegylated recombinant human hyaluronidase)	II	ibrutinib + gemcitabine + nabpaclitaxel	Borderline resectable and LAPC	[89]
	3. Pamrevlumab (anti-connective tissue growth factor)	II	PEGPH20 + nab-paclitaxel + gemcitabine vs nab-paclitaxel + gemcitabine PEGPH20 + FOLFIRINOX vs FOLFIRINOX Gemcitabine + nab-paclitaxel + pamrevlumab vs gemcitabine + nab-paclitaxel	First line First line LAPC	[93] [94] [97]
Cancer Stem Cells inhibitors	napabucasin	Ib	ibrutinib + gemcitabine + nabpaclitaxel	First line	[92]
	napabucasin	Ib	napabucasin + gemcitabine + nab-paclitaxel	All lines for advanced disease	[98]

Table 2
Selected ongoing clinical trials.

Mechanism of action	Drugs	Phase	Setting	Trial identification number
Mek1/2 inhibitor + CDK4/6 inhibitor	trametinib + ribociclib	I-II	LAPC and MPC	NCT02703571
TGF-β inhibitor + anti-PD-1	galunisertib + durvalumab	I	Second and third line	NCT02734160
PARP-inhibitors	1. rucaparib 2. gencitabine and cisplatin with or without veliparib or veliparib alone	II	Maintenance in BRCA1-2or PALB2 mutated MPC after platinum-based therapy LAPC and MPC	NCT03140670
Anti-CCR2	PF-04136309 + gencitabine + nab-paclitaxel vs gencitabine + nab-paclitaxel + placebo	II	First line MPC	NCT01585805
ECM inhibitors	1. PEGPH20 + gencitabine + nab-paclitaxel vs gencitabine + nab-paclitaxel + placebo 2. Pamrevlumab + gencitabine + nab-paclitaxel vs placebo + gencitabine + nab-paclitaxel	III	First line MPC	NCT02715804
Cancer stem cells inhibitor	Napabucasin + gencitabine + nab-paclitaxel vs gencitabine + nab-paclitaxel	III	First line MPC	NCT02993731

DNA repair factors inhibitors: Poly ADP ribose polymerase inhibitors (PARPi)

Preliminary evidence of disease control with olaparib was provided by the results of a multi-tumour type phase 2 study which included 23 BRCA1-2 mutant PDAC patients [70].

Recently, the results of the international, randomized, double-blind, placebo-controlled phase III POLO trial of olaparib maintenance after ≥ 16 weeks of first-line platinum-based chemotherapy were published. MPC patients harbouring germline BRCA mutations were randomized 3:2 to maintenance olaparib (90 patients) or placebo (61 patients). mPFS (primary endpoint) was improved with olaparib (7.4 months vs 3.8 months with placebo, HR = 0.53, $p = 0.004$), irrespective of the response to induction chemotherapy; safety was consistent with its known adverse event profile [71].

The RUCAPANC trial investigated the efficacy and safety of rucaparib in refractory, BRCA1/2-mutant LAPC and MPC. Four out of 19 patients enrolled achieved a response; two PR and one CR were confirmed (ORR = 15.8%). The disease control rate (CR, PR, or SD for ≥ 12 weeks) was 31.6% in all patients and 44.4% in those who had received one prior chemotherapy regimen. However, despite an acceptable safety profile, enrolment was stopped as prespecified in the protocol because of an insufficient ORR among the first 15 patients [72].

An ongoing phase 2 study (NCT03140670) is evaluating the role of rucaparib maintenance in BRCA1-2 or PALB2 mutated PDAC after platinum-based treatment.

A multicentre single-arm phase II trial evaluated the ORR of veliparib in patients with previously treated BRCA1/2- or PALB2-mutant PDAC. No confirmed ORR were seen: one (6%) unconfirmed PR was observed at 4 months with disease progression (PD) at 6 months; four patients (25%) had SD, 11 (69%) had PD. mPFS was 1.7 months (95%CI:1.57–1.83) and mOS was 3.1 months (95%CI:1.9–4.1) [73].

Pishvaian et al. conducted a phase I/II trial of veliparib plus FOLFFOX6 in MPC. The phase II part of the study included a treatment-naïve and a refractory patient cohort and recruitment was limited to patients with pathogenic germline or somatic DDR mutation (BRCA1/2, PALB2, ATM), and/or a family history suggestive of a breast or ovarian cancer syndrome (FH+). Veliparib plus FOLFFOX resulted safe and well tolerated; the primary endpoint of ORR $\geq 25\%$ was reached and platinum-naïve, FH+ and DDR mutation positive patients had an ORR of 58% [74].

Veliparib was also evaluated in combination with FOLFIRI vs FOLFIRI alone for second-line treatment in a randomized phase II trial. While the trial didn't have a biomarker-driven recruitment strategy, nearly 30% of patients had DDR gene abnormalities, including 9% with homologous recombination deficiency (HRD). Veliparib increased toxicity but didn't improve OS [75].

A phase 2 study of veliparib plus or minus gencitabine and cisplatin vs gencitabine and cisplatin alone in LAPC and MPC is ongoing (NCT01585805).

Immunotherapy

In contrast to other solid tumours, immunotherapy has not shown brilliant results in PDAC so far. This is possibly due to the immune suppressive tumour microenvironment (with stromal infiltration of myeloid-derived suppressor cells, and tumour-associated macrophages) and overall low mutational load [76–77]. In clinical trials, neither ipilimumab nor nivolumab showed objective response [78,79]. However, pembrolizumab was associated with interesting ORR in MSI-H PDAC patients [80].

Anti-CTLA4 inhibitors and anti-PD-1 inhibitors are currently being investigated in combination with standard gencitabine chemotherapy in clinical trials [81–84].

Interesting results are rising from the combination with vaccines, as

in the case of GVAX, whole-cell vaccine composed of irradiated and allogeneic PC cells genetically engineered to secrete granulocyte-macrophage colony-stimulating factor, which stimulates dendritic cell activation and T-cell priming [85–87].

2,3-dioxygenase (IDO) up-regulation is one mechanism of resistance to immunotherapy since it inhibits T-cells response. An IDO inhibitor, indoximod, showed a 37% ORR at the interim analyses of a phase 2 trial in combination with gemcitabine and nab-paclitaxel [88].

A phase Ib trial was conducted in borderline-resectable and LAPC patients to assess the efficacy of the CCR2 inhibitor, PF-04136309, with FOLFIRINOX; an ORR of 49% was reported [89].

A phase 2 clinical trial evaluating the efficacy of PF-04136309 in combination with gemcitabine and nab-paclitaxel in MPC patients is in progress (NCT02732938).

ECM

Ibrutinib, a Bruton's tyrosine kinase inhibitor, showed inhibition of mast cells and tumour progression in a mouse model of b-cell tumorigenesis. Moreover, it was proven to be highly effective in limiting PDAC growth in transgenic mice and patient-derived xenograft disease models [90,91]. Unfortunately, the RESOLVE trial, a randomized, double-blind, placebo-controlled study of ibrutinib with nab-paclitaxel and gemcitabine in the first-line treatment of patients with MPDPC showed no improvement in OS or PFS in the intent-to-treat population [92].

The pegylated recombinant human hyaluronidase (PEGPH20) was first investigated in naïve PDAC patients in the phase 2 HALO 202 trial. PEGPH20 in combination with gemcitabine and nab-paclitaxel improved PFS only in patients with high HA expression [93]. Further to the results of subgroup analyses, recruitment into the ongoing phase 3 trial has been limited to patients with HA-high tumours (NCT02715804).

PEGPH20 efficacy was investigated also in the SWOG S1313 trial, a phase Ib/II study of modified FOLFIRINOX plus PEGPH20 vs FOLFIRINOX alone in MPC patients, but the addition of PEGPH20 to FOLFIRINOX was detrimental (mOS: 14.4 months in the standard arm vs 7.7 months in the combination arm) [94].

Pamrevlumab, a mAb targeting the connective tissue growth factor, showed encouraging preclinical results [95,96]. Therefore, a phase 2 randomized study of gemcitabine and nab-paclitaxel +/- pamrevlumab in treatment-naïve LAPC patients was designed to evaluate resection rates and OS. Among patients who completed 6 cycles of treatment, 78% in the investigational arm and 17% in the control arm were resectable, while 44% and 17%, respectively, underwent resection [97]. An international phase 3, randomized, double-blind trial to evaluate the efficacy and safety of neoadjuvant treatment with pamrevlumab plus gemcitabine plus nab-paclitaxel versus placebo plus gemcitabine plus nab-paclitaxel for unresectable LAPC is ongoing (NCT03941093).

CSCs inhibitors

Preclinical evidence showed that napabucasin, an anti-STAT3, sensitizes cancer cells to chemotherapy drugs, including nab-paclitaxel and gemcitabine. 37 MPC patients were enrolled in a phase Ib study of napabucasin + gemcitabine and nab-paclitaxel. Out of 29 evaluable patients, 27 (93%) achieved disease control, while 23 (79.3%) had tumour regression. PR was reported in 10 (34.5%) patients [98]. Based on these results, a phase III study has been launched (CanStem111P test) where patients are randomized to receive standard gemcitabine plus nab-paclitaxel or the same treatment plus napabucasin [99].

Conclusion

Despite the recent increased number of treatment options, PC still

shows modest response to conventional cytotoxic drugs and a dismal prognosis. This is partly due to the unique characteristics of the tumour microenvironment which is poorly immunogenic and largely composed of a highly desmoplastic stroma. Also, activation of oncogenic signalling pathways and frequent EMT dysregulation likely contribute to PDAC biological aggressiveness. While sophisticated studies allowed dissecting the genomic complexity of PC and the functional relevance of the surrounding stroma, no driver tumour genes or stromal elements have yet been validated as useful therapeutic targets. With the only exception of olaparib for BRCA mutant patients, the mainstay of treatment for advanced PDAC remains cytotoxic chemotherapy with targeted therapies and immune modulatory strategies yielding disappointing results so far.

PDAC is projected to become the second leading cause of cancer-related death by 2030. This alarming projection should prompt researchers to pursue further analysis of the mechanistic bases of treatment response/resistance and investigation of potentially game-changing treatment options. The available genomic data should be the base for development of biomarker-driven clinical trials. In the Era of precision medicine the optimal therapeutic management should be guided by high-sensitive and high-specific available biomarkers, able to define the biomolecular cancer cell profile. One of the major hurdles is that the PDAC biomolecular profile is spatial and temporal heterogeneous. In this regard, large studies are needed to validate new biomarkers for clinical application, investigating the most appropriate procedure to identify and to follow the dynamic biomarker-state.

Finally, combination treatment strategies including chemotherapy, targeted therapy, immunotherapy and stromal targeting drugs represent the most promising line of research.

Acknowledgements- Contributors

All Authors have materially participated in research and/or article preparation and made substantial contribution to the conception and design of the article or the acquisition of data or analysis and interpretation of data. E.L., M.S., M.P. and P.Z. conceived the manuscript; E.L. and M.S. wrote the manuscript. M.P., P.Z, A. Pretta and F.S. provided writing assistance and language help. All Authors did the literature search. A. Pretta conceived the figure, E.L. and S.M. conceived the tables. V.I., S.M., N.L., P.S., F.M., M.P., C.D., S.T., F.B., A. Pireddu, L.D., V.P., S.C., provided writing assistance. All authors critically revised the draft for important intellectual content and approved the final article.

Declaration of Competing Interest

None. All Authors have approved the final article.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

- [1] Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, et al. Genetics and biology of pancreatic ductal adenocarcinoma. *Genes Dev* 2016;30:355–85.
- [2] Brunetti O, Luchini C, Argentiero A, Tommasi S, Mangia A, Aprile G, et al. The Italian rare pancreatic exocrine cancer initiative. *Tumori* 2019. <https://doi.org/10.1177/0300891619839461>. 300891619839461, PubMed PMID: 30967031.
- [3] Brunetti O, Aprile G, Marchetti P, Vasile E, Casadei Gardini A, Scartozzi M, et al. Systemic chemotherapy for advanced rare pancreatic histotype tumors: a retrospective multicenter analysis. *Pancreas* 2018;47(6):759–71. <https://doi.org/10.1097/MPA.0000000000001063>. PubMed PMID: 29771769.
- [4] Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. *Cancer Res* 2014;74:2913–21.
- [5] Hidalgo M, Cascinu S, Kleeff J, Labianca R, Lohr JM, Neoptolemos J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. *Pancreatology* 2015;15:8–18.

- [6] Pierantoni C, Pagliacci A, Scartozzi M, Berardi R, Bianconi M, Cascinu S. Pancreatic cancer: progress in cancer therapy. *Crit Rev Oncol Hematol* 2008;67(1):27–38. <https://doi.org/10.1016/j.critrevonc.2008.01.009>. Review. PubMed PMID: 18356073.
- [7] Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J Clin Oncol* 1997;15:2403–13.
- [8] Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécauarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011;364:1817–25. <https://doi.org/10.1056/NEJMoa1011923>.
- [9] Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *N Engl J Med* 2013;369:1691–703.
- [10] Aprile G, Negri FV, Giuliani F, De Carlo E, Melisi D, Simonato F, et al. Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? *Crit Rev Oncol Hematol* 2017;115(1–12):6. <https://doi.org/10.1016/j.critrevonc.2017.03.025>. PubMed PMID: 28602164.
- [11] Aslan M, Shahbazi R, Ulubayram K, Ozpolat B. Targeted therapies for pancreatic cancer and hurdles ahead. *Anticancer Res* 2018;38(12):6591–606. <https://doi.org/10.21873/anticancer.13026>.
- [12] Collisson EA, Bailey P, Chang D, Biankin AV. Molecular subtypes of pancreatic cancer. *Nat Rev Gastroenterol Hepatol* 2019;16(4):207–20. <https://doi.org/10.1038/s41575-019-0109-y>.
- [13] Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. *Nat Rev Dis Primers* 2016;2(12):16022. <https://doi.org/10.1038/nrdp.2016.22>.
- [14] Garber K. Stromal depletion goes on trial in pancreatic cancer. *J Natl Cancer Inst* 2010;102(7):448–50. <https://doi.org/10.1093/jnci/djq113>. Epub 2010 Mar 25.
- [15] Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. *Nat Genet* 2015;47(10):1168–78. <https://doi.org/10.1038/ng.3398>. Epub 2015 Sep 7.
- [16] Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. *Nature* 2016;531(7592):47–52. <https://doi.org/10.1038/nature16965>.
- [17] Raphael BJ, Hruban RH, Aguirre AJ, Moffitt RA, Yeh JJ, Stewart C, et al. Integrated genomic characterization of pancreatic ductal adenocarcinoma. *Cancer Cell* 2017;32(2):185–203.e13. <https://doi.org/10.1016/j.ccell.2017.07.007>.
- [18] Somerville TD, Xu Y, Miyabayashi K, Tiriac Hervé, Cleary Cristian R, Maia-Silva Diogo, et al. TP63-Mediated enhancer reprogramming drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma. *Cell Rep* 2018;25(7):1741–55. <https://doi.org/10.1016/j.celrep.2018.10.051>. e7.
- [19] Hingorani SR, Wang L, Multani AS, Combs C, Deramautd TB, Hruban RH, et al. Trp53R172H and KRASG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. *Cancer Cell* 2005;7(5):469–83.
- [20] Jia D, Sun Y, Konieczny Stephen F. Mist1 regulates pancreatic acinar cell proliferation through p21 CIP1/WAF1. *Gastroenterology* 2008;135(5):1687–97. <https://doi.org/10.1053/j.gastro.2008.07.026>.
- [21] Xiaodiao K, Zeng L, Minhui X, Pan J, Wang ZW. Deciphering role of FGFR signalling pathway in pancreatic cancer. *Cell Prolif* 2019;3:e12605. <https://doi.org/10.1111/cpr.12605>.
- [22] Ebrahimi S, Hosseini M, Shahidsales S, Maftouh M, Ferns GA, Ghayour-Mobarhan M, et al. Targeting the Akt/PI3K signaling pathway as a potential therapeutic strategy for the treatment of pancreatic cancer. *Curr Med Chem* 2017;24(13):pp. <https://doi.org/10.2174/0929867324666170206142658>.
- [23] Conway JRW, Herrmann D, Evans TRJ, Morton Jennifer P, Timpson Paul. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Recent advances in basic science 5 November 2018. <https://doi.org/10.1136/gutjnl-2018-316822>.
- [24] Polireddy K, Chen QI. Cancer of the pancreas: molecular pathways and current advancement in treatment. *J Cancer* 2016;7(11):1497–514.
- [25] Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri DG, et al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. *N Engl J Med* 2018;378(8):731–9. <https://doi.org/10.1056/NEJMoa1714448>.
- [26] Miknyoczki SJ, Lang D, Huang L, Klein-Szanto AJ, Dionne CA, Ruggeri BA. Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: expression patterns and effects on in vitro invasive behavior. *Int J Cancer* 1999;81:417–27. [https://doi.org/10.1002/\(SICI\)1097-0215\(19990505\)81:3<417::AID-IJC16>3.0.CO;2-6](https://doi.org/10.1002/(SICI)1097-0215(19990505)81:3<417::AID-IJC16>3.0.CO;2-6).
- [27] Sahin IH, Iacobuzio-Donahue CA, O'Reilly EM. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. *Expert Opin Ther Targets* 2016;20(3):341–59.
- [28] Sano M, Driscoll DR, DeJesus-Monge WE, Quattrochi B, Appleman VA, Ou J, et al. Activation of WNT/β-catenin signaling enhances pancreatic cancer development and the malignant potential via Up-regulation of Cyr61. *Neoplasia* 2016;18(12):785–94. <https://doi.org/10.1016/j.neo.2016.11.004>.
- [29] Escot S, Willnow D, Naumann H, Di Francesantonio S, Spagnoli MF. Robo signalling controls pancreatic progenitor identity by regulating Tead transcription factors. *Nat Commun* 2018;9(1):5082. <https://doi.org/10.1038/s41467-018-07474-6>.
- [30] Pinho AV, Van Bulck M, Chantrill L, Arshi M, Sklyarova T, Herrmann D, et al. ROBO2 is a stroma suppressor gene in the pancreas and acts via TGF-β signaling. *Nat Commun* 2018;9(1):5083. <https://doi.org/10.1038/s41467-018-07497-z>.
- [31] Van Mackelenbergh MG, Stroes CI, Spijker R, an Eijck CHJ, Wilmsink JW, Bijlsma MF, et al. Clinical trials targeting the stroma in pancreatic cancer: a systematic review and meta-analysis. *Cancers (Basel)* 2019;11(5). <https://doi.org/10.3390/cancers11050588>. pii: E588.
- [32] Niyaz M, Khan MS, Wani RA, Shah OJ, Mudassar S. Sonic hedgehog protein is frequently up-regulated in pancreatic cancer compared to colorectal cancer. *Pathol Oncol Res* 2018. <https://doi.org/10.1007/s12253-018-00564-2>.
- [33] Ma Y, Yu W, Shrivastava A, Srivastava RK, Shankar S. Inhibition of pancreatic cancer stem cell characteristics by α-Mangostin: Molecular mechanisms involving Sonic hedgehog and Nanog. *J Cell Mol Med* 2019;23:2719–30. <https://doi.org/10.1111/jcmm.14178>.
- [34] Heining C, Horak P, Uhrig S, Codo PL, Klink B, Hutter B, et al. NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer. *Cancer Discov* 2018;8(9):1087–95. <https://doi.org/10.1158/2159-8290.CD-18-0036>.
- [35] Pihlak R, Valle JW, McNamara MG. Germline mutations in pancreatic cancer and potential new therapeutic options. *Oncotarget* 2017;8(42):73240–57. <https://doi.org/10.18632/oncotarget.17291>.
- [36] Lal G, Liu G, Schmocker B, Kaurah P, Ozelik H, Narod SA, et al. Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. *Cancer Res* 2000;60:409–16.
- [37] Iqbal J, Ragone A, Lubinski J, Lynch HT, Moller P, Ghadirani P, et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. *Br J Cancer* 2012;107(12):2005–9. <https://doi.org/10.1038/bjc.2012.483>.
- [38] Macherla S, Laks S, Naqash AR, Bulumulle A, Zervos E, Muzaffar M, et al. Emerging role of immune checkpoint blockade in pancreatic cancer. *Int J Mol Sci* 2018;19(11). <https://doi.org/10.3390/ijms19113505>. pii: E3505.
- [39] Huang H, Brekken RA. The Next wave of stroma-targeting therapy in pancreatic cancer. *Cancer Res* 2019;79(2):328–30. <https://doi.org/10.1158/0008-5472.CAN-18-3751>.
- [40] Erdogan Begum, Webb Donna J. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. *Biochem Soc Trans* 2017;45(1):229–36. <https://doi.org/10.1042/BST20160387>.
- [41] Awaji M, Singh RK. Cancer-associated fibroblasts' functional heterogeneity in pancreatic ductal adenocarcinoma. *Cancers (Basel)* 2019;11(3). <https://doi.org/10.3390/cancers11030290>.
- [42] Wong M, Horton KJ, Coveler AL, Hingorani SR, Harris WP. Targeting the tumor stroma: the biology and clinical development of pegylated recombinant human hyaluronidase (PEGPH20). *Curr Oncol Rep* 2017 Jul;19(7):47. <https://doi.org/10.1007/s11912-017-0608-3>.
- [43] Hou YC, Chao YJ, Hsieh MH, Tung HL, Wang HC, Shan YS. Low CD8 + T Cell Infiltration and High PD-L1 Expression Are Associated with Level of CD44 + / CD133 + Cancer Stem Cells and Predict an Unfavorable Prognosis in Pancreatic Cancer. *Cancers (Basel)* 2019;11(4). <https://doi.org/10.3390/cancers11040541>. pii: E541.
- [44] Infante JR, Somer BG, Park JO, Li CP, Scheulen ME, Kasubhai SM, et al. A randomized, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. *Eur J Cancer* 2014;50:2072–81. <https://doi.org/10.1016/j.ejca.2014.04.024>.
- [45] Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, Pover G, et al. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. *Investig New Drugs* 2012;30(3):1216–23. <https://doi.org/10.1007/s10637-011-9687-4>.
- [46] Aung KL, McWhirter E, Welch S, Wang L, Lovell S, Stayner LA, et al. A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (MOBILITY-002 Trial, NCT02428270). *J Clin Oncol* 2018;36(no. 4 suppl):409. https://doi.org/10.1200/JCO.2018.36.4_suppl.409.
- [47] Walsh AJ, Castellanos JA, Nagathihalli NS, Merchant NB, Skala MC. Optical imaging of drug-induced metabolism changes in murine and human pancreatic cancer organoids reveals heterogeneous drug response. *Pancreas* 2016;45(6):863–9. <https://doi.org/10.1097/MPA.0000000000000543>.
- [48] Kindler H, Richards D, Garbo L, Garon EB, Stephenson Jr JJ, Rocha-Lima CM, et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. *Ann Oncol* 2012 Nov;23(11):2834–42. <https://doi.org/10.1093/annonc/mds142>.
- [49] Rosen LS, Puzanov I, Friberg G, Chan E, Hwang YC, Deng H, et al. Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors. *Clin Cancer Res* 2012;18(12):3414–27. <https://doi.org/10.1158/1078-0432.CCR-11-3369>.
- [50] Fuchs CS, Azevedo S, Okusaka T, Van Laethem JL, Lipton LR, Riess H, et al. A phase 3 randomized, double-blind, placebo controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. *Ann Oncol* 2015;26(5):921–7. <https://doi.org/10.1093/annonc/mdv027>.
- [51] Pace E, Adams S, Camblin A, Curley Michael, Rimkunas Victoria, Nie Lin, et al. Effect of MM-141 on gemcitabine and nab-paclitaxel potentiation in preclinical models of pancreatic cancer through induction of IGF-1R and ErbB3 degradation. *J Clin Oncol* 2015;33(3 suppl Jan 20 2015):289.
- [52] Ko AH, Cubillo A, Kundranda M, Zafar SF, Meiri E, Bendell J, et al. CARRIE: A randomized, double-blind, placebo-controlled phase II study of istratimumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer. *Ann Oncol* 2018;29(Issue suppl.8). <https://doi.org/10.1093/annonc/mdy424.031>.
- [53] Wolpin BI, Hezel AF, Abrams T, Blazskowsky LS, Meyerhardt JA, Chan JA, et al.

- Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. *J Clin Oncol* 2009;27(2):193–8. <https://doi.org/10.1200/JCO.2008.18.9514>.
- [54] Karavasiliou V, Samantas E, Koliou GA, Kalogera-Fountzila A, Pentheroudakis G, Vartholitis I, et al. Gemcitabine Combined with the mTOR inhibitor temsirolimus in patients with locally advanced or metastatic pancreatic cancer. A Hellenic Cooperative Oncology Group Phase I/II Study. *Target Oncol* 2018;13(6):715–24. <https://doi.org/10.1007/s11523-018-0605-y>.
- [55] Drilon A, Siena S, Ou SHI, Patel M, Ahn MJ, Lee J, et al. Safety and Antitumor Activity of the Multi-Targeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib (RXDX-101): Combined Results from Two Phase 1 Trials (ALKA-372-001 and STARTRK-1). *CancerDiscov* 2017;7(4):400–9. <https://doi.org/10.1158/2159-8290.CD-16-1237>.
- [56] Smith DC, Eisenberg PD, Manikhas G, Chugh R, Gubens MA, Stagg RJ, et al. A phase I dose escalation and expansion study of the anticancer stemcell agent demcizumab (anti-DLL4) in patients with previously treated solid tumors. *Clin Cancer Res* 2014;20(24):6295–303. <https://doi.org/10.1158/1078-0432.CCR-14-1373>.
- [57] Abrams MJ, Rakaszawski K, Vasekar M, Frank Passero, Abbas Atif, Jia Yuxia, et al. Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology. *Therap Adv Gastroenterol* 2016;9(2):141–51. <https://doi.org/10.1177/1756283X15622601>.
- [58] Cubillo Gracian A, Dean A, Muñoz A, Hidalgo M, Pazo-Cid R, Martin M, et al. YOSEMITE: a 3 arm double-blind randomized phase 2 study of gemcitabine, paclitaxel protein-bound particles for injectable suspension, and placebo (GAP) versus gemcitabine, paclitaxel protein-bound particles for injectable suspension and either 1 or 2 truncated courses of demcizumab (GAD). *Ann Oncol* 2017;28(suppl 5):620.
- [59] O'Reilly EM, Sahai V, Bendell JC, Bullock AJ, LoConte NK, Hatoum H, et al. Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P + Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC). *J Clin Oncol* 2017;35(no. 4, suppl):279. https://doi.org/10.1200/JCO.2017.35.4_suppl.279.
- [60] De Jesus-Acosta A, Laheru D, Maitra A, Arcaroli J, Rudek MA, Dasari A, et al. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. *Investig New Drugs* 2014;32(4):739–45. <https://doi.org/10.1007/s10637-014-0083-8>.
- [61] Cook N, Basu B, Smith DM, Gopinathan A, Evans J, Steward WP, et al. A phase I trial of the c-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. *Br J Cancer* 2018;118(6):793–801. <https://doi.org/10.1038/bjc.2017.495>.
- [62] Melisi D, Garcia-Carbonero R, Macarulla T, Pezet D, Deplanque G, Fuchs M, et al. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. *Br J Cancer* 2018;119(10):1208–14. <https://doi.org/10.1038/s41416-018-0246-z>.
- [63] Ko AH, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, et al. A phase I study of FOLFIRINOX plus IPI-926, a hedgehog pathway inhibitor, for advanced pancreatic adenocarcinoma. *Pancreas* 2016;45(3):370–5. <https://doi.org/10.1097/MPA.0000000000000458>.
- [64] Stephenson J, Richards DA, Wolpin BM, Becerra C, Hamm JT, Messersmith WA, et al. The safety of IPI-926, a novel hedgehog pathway inhibitor, in combination with gemcitabine in patients (pts) with metastatic pancreatic cancer. *J Clin Oncol* 2011;29(no. 15, suppl):4114. https://doi.org/10.1200/jco.2011.29.15_suppl.4114.
- [65] Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, et al. Randomized phase Ib/II study of gemcitabine plus placebo or Vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic Cancer. *J Clin Oncol* 2015;33(36):4284–92. <https://doi.org/10.1200/JCO.2015.62.8719>.
- [66] Franco J, Witkiewicz AK, Knudsen ES. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. *Oncotarget* 2014;5(15):6512–25.
- [67] Leontieva O, Demidenko Z, Blagosklonny M. MEK drives cyclin D1 hyperlevelation during geronconversion. *Cell Death Differ* 2013;20(9):1241–9. <https://doi.org/10.1038/cdd.2013.86>.
- [68] Leontieva OV, Blagosklonny MV. CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: duration of cell cycle arrest and MTOR activity determine geronconversion. *Cell Cycle* 2013;12(18):3063–9. <https://doi.org/10.4161/cc.26130>.
- [69] Schettini F, De Santo I, Rea CG, De Placido P, Formisano L, Giuliano M, et al. CDK 4/6 inhibitors as single agent in advanced solid tumors. *Front Oncol* 2018;8:608. <https://doi.org/10.3389/fonc.2018.0608>.
- [70] Golan T, Kanji Z, Epelbaum R, Devaud N, Dagan E, Holter S, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. *Br J Cancer* 2014;111(6):1132–8. <https://doi.org/10.1038/bjc.2014.418>.
- [71] Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. *N Engl J Med* 2019. <https://doi.org/10.1056/NEJMoa1903387>.
- [72] Shroff RT, Hendifar A, McWilliams RR, Geva R, Epelbaum R, Rolfe L, et al. Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation. *JCO Precis Oncol* 2018;2018. <https://doi.org/10.1200/PO.17.00316>.
- [73] Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, et al. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreatic ductal adenocarcinoma. *Eur J Cancer* 2018;89:19–26. <https://doi.org/10.1016/j.ejca.2017.11.004>.
- [74] Pishvaian MJ, Wang H, Parenti S, He AR, Hwang JJ, Ley L, et al. Final report of a phase I/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients (pts) with metastatic pancreatic cancer (mPDAC). *J Clin Oncol* 2019;37(no. 15, suppl):4015. https://doi.org/10.1200/JCO.2019.37.15_suppl.4015.
- [75] Chiorean EG, Guthrie KA, Agop P, Swisher EM, Jalikis F, Pishvaian MJ, et al. Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513. *J Clin Oncol* 2019;37(no. 15, suppl):4014. https://doi.org/10.1200/JCO.2019.37.15_suppl.4014.
- [76] Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. *Nature* 2013;500:415–21. <https://doi.org/10.1038/nature12477>.
- [77] Wachsmann MB, Pop LM, Vitetta ES. Pancreatic ductal adenocarcinoma: a review of immunologic aspects. *J Investig Med* 2012 Apr;60(4):643–63. <https://doi.org/10.2310/JIM.0b013e31824a4d79>.
- [78] Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. *J Immunother* 2010;33(8):828–33. <https://doi.org/10.1097/CJI.0b013e3181e1ec14c>.
- [79] Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N Engl J Med* 2012;366(26):2455–65. <https://doi.org/10.1056/NEJMoa1200694>.
- [80] Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* 2017;357(6349):409–13. <https://doi.org/10.1126/science.aan6733>.
- [81] Aglietta M, Barone C, Sawyer MB, Moore MJ, Miller Jr WH, Bagalà C, et al. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naïve patients with metastatic pancreatic cancer. *Ann Oncol* 2014;25(9):1750–5. <https://doi.org/10.1093/annonc/mdl205>.
- [82] Mohindra NA, Kircher SM, Nimeiri HS, Benson AB, Rademaker A, Alonso E, et al. Results of the phase Ib study of ipilimumab and gemcitabine for advanced pancreas cancer. 2015 GI ASCO Annual Meeting. *J Clin Oncol* 2015;33. https://doi.org/10.1200/jco.2015.33.15_suppl.e15281.
- [83] Kalyan A, Kircher SM, Mohindra NA, Nimeiri HS, Maurer V, Rademaker A, et al. GI ASCO Annual Meeting. *J Clin Oncol* 2016;2016(34):e15747. https://doi.org/10.1200/JCO.2016.34.15_suppl.e15747.
- [84] Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. *Clin Cancer Res* 2007;13(7):2151–7.
- [85] Lutz E, Yeo CJ, Lillemo KD, Biedrzycki B, Kobrin B, Herman J, et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. *Ann Surg* 2011;253(2):328–35. <https://doi.org/10.1097/SLA.0b013e3181fd271c>.
- [86] Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. *Cancer Immunol Res* 2014;2(7):616–31. <https://doi.org/10.1158/2326-6066.CIR-14-0027>.
- [87] Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. *J Immunother* 2013;36(7):382–9. <https://doi.org/10.1097/CJI.0b013e31829fb7a2>.
- [88] Bahary N, Garrido-Laguna I, Cinar P, O'Rourke KA, Somer BG, Nyak-Kapoor A, et al. Phase 2 trial of the indoleamine 2, 3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas cancer: interim analysis. *J Clin Oncol* 2016;34(no. 15, suppl):3020. https://doi.org/10.1200/JCO.2016.34.15_suppl.3020.
- [89] Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-Centre, open-label, dose-finding, nonrandomised, phase 1b trial. *Lancet Oncol* 2016;17(5):651–62. [https://doi.org/10.1016/S1470-2045\(16\)00078-4](https://doi.org/10.1016/S1470-2045(16)00078-4).
- [90] Masso-Valles D, Jauset T, Serrano E, Sodr NM, Pedersen K, Affara NI, et al. Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma. *Cancer Res* 2015;75(8):1675–81. <https://doi.org/10.1158/0008-5472.CAN-14-2852>.
- [91] Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas Cancer. *Cancer Discov* 2016;6(3):270–85. <https://doi.org/10.1158/2159-8290.CD-15-0827>.
- [92] Tempero M, Oh D, Macarulla T, Reni M, Van Cutsem E, Hendifar A, et al. Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study. *Ann Oncol* 2019;30(Supplement 4):1. <https://doi.org/10.1093/annonc/mdz154.001>.
- [93] Hingorani SR, Zheng L, Bullock AJ, et al. HALO 202: randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine versus nab-paclitaxel/ gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma. *J Clin Oncol* 2018;36(4):359–66. https://doi.org/10.1200/JCO.2016.34.15_suppl.TPS2601.
- [94] Ramanathan RK, McDonough SL, Philip PA, Hingorani SR, Lacy J, Kortmansky JS, et al. A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + pegylated recombinant human hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313. *J Clin Oncol* 2019;37(13):1062–9. <https://doi.org/10.1200/JCO.18.01295>.
- [95] Neeße A, Frese KK, Bapiro TE, Nakagawa T, Sternlicht MD, Seeley TW, et al. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. *Proc Natl Acad Sci U S A* 2013;110(30):12325–30. <https://doi.org/10.1073/pnas.1300415110>.
- [96] Dornhöfer N, Spong S, Bennewit K, Salim A, Klaus S, Kambham N, et al.

- Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. *Cancer Res* 2006;66(11):5816–27.
- [97] Carrier E, Picozzi V, Pishvaian M, Mody K, Winter J, Glaspy J, et al. Anti-CTGF human recombinant monoclonal antibody pamrevlumab increases resectability and resection rate when combined with gemcitabine/nab-paclitaxel in the treatment of locally advanced pancreatic cancer patients. *Ann Oncol* 2017;28(suppl_5):1734PD.
- [98] El-royes, Shahda S, Starodub A, O'Neil BH, Hanna WT, Shaib WL, et al. A phase Ib extension study of cancer stemness inhibitor BB608 (napabucasin) in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic cancer. *J Clin Oncol* 2016;34(15_suppl):4128. https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS4148.
- [99] Bekaii-Saab T, Li CP, Okusaka T, O'Neil BH, Reni M, Tabernero J, et al. CanStem111P trial: A Phase 3 Study of napabucasin (NAPA) plus nab-paclitaxel (nPTX) with gemcitabine (Gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC) - Trial in progress. *J Clin Oncol* 2017;35(15_suppl). https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS4148.